Esperion to Participate in Two Upcoming Virtual Investor Conferences
September 02 2020 - 8:41AM
Esperion (NASDAQ: ESPR), today announced that members of Esperion
management will participate in two upcoming virtual conferences
during the month of September.
Event: |
Citi 15th
Annual Biopharma Conference |
Date: |
September 9, 2020 |
Format: |
1:1 Investor meetings |
|
|
Event: |
Morgan Stanley 18th Annual Global Healthcare Conference |
Date: |
September 14, 2020 |
Format: |
Fireside chat & 1:1 Investor meetings |
Time: |
3:45 p.m. ET |
A live audio webcast of the Morgan Stanley 18th Annual Global
Healthcare Conference fireside chat can be accessed on the investor
relations section of the Esperion website at
www.esperion.com/investors-media/events-presentations/. Replay of
the webcast will be archived on the Company's website for 90 days
following the event.
Esperion Therapeutics
Through scientific and clinical excellence, and a deep
understanding of cholesterol biology, the experienced Lipid
Management Team at Esperion is committed to developing new LDL-C
lowering medicines that will make a substantial impact on reducing
global cardiovascular disease, the leading cause of death around
the world. For more information, please visit www.esperion.com and
follow us on Twitter at www.twitter.com/EsperionInc.
Esperion Therapeutics’ Commitment to Patients with
Hyperlipidemia
High levels of LDL-C can lead to a build-up of fat and
cholesterol in and on artery walls (known as atherosclerosis),
potentially leading to cardiovascular events, including heart
attack and stroke. In the U.S., 96 million people, or more than 37
percent of the adult population, have elevated LDL-C. There are
approximately 18 million people in the U.S. living with elevated
levels of LDL-C despite taking maximally tolerated lipid-modifying
therapy — including individuals considered statin averse — leaving
them at high risk for cardiovascular events1. In the United States,
more than 50 percent of atherosclerotic cardiovascular disease
(ASCVD) patients and heterozygous familial hypercholesterolemia
(HeFH) patients who are not able to reach their guideline
recommended LDL-C levels with statins alone need less than a 40
percent reduction to reach their LDL-C threshold goal2.
Esperion's mission as the Lipid Management Company is to deliver
oral, once-daily medicines that complement existing oral drugs to
provide the additional LDL-C lowering that these patients need.
References (1) Esperion market
research on file: research project interviewing 350 physicians.
Esperion Therapeutics, Inc. Sept-Oct 2018. (2) Data on
file: analysis of NHANES database. Esperion Therapeutics, Inc.
2018.
Investor Contact:Kaitlyn
BroscoEsperioninvestorrelations@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Apr 2023 to Apr 2024